Table 1. CR rates of patients with advanced NSCLC in major clinical trials.
| Variables | Clinical trial | Phase | Treatment | Patients | CR rate of target lesions [% (n/N)] | ORR [% (n/N)] | Reference |
| CR, complete remission; NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; RET, ret proto-oncogene; KRAS, Kirsten rat sarcoma viral oncogene homolog; PD-L1, programmed death-ligand 1; TPS, tumor proportion score; ES, extensive stage; ORR, overall response rate. | |||||||
| Target therapy | |||||||
| First-line | FLAURA (NCT02296125) | III | Osimertinib | EGFR mutation | 3 (7/279) | 80 (223/279) | (12) |
| NEJ009 (UMIN000006340) | III | Gefitinib vs. Gefitinib + Carboplatin | EGFR mutation | 3 (5/173) vs.
4 (7/172) |
67 (116/173) vs. 84 (144/172) | (13) | |
| NEJ026 (UMIN000017069) | III | Erlotinib + Bevacizumab vs. Erlotinib | EGFR mutation | 7 (8/112) vs.
4 (4/112) |
72 (81/112) vs. 66 (74/112) | (14) | |
| ARCHER 1050 (NCT01774721) | III | Dacomitinib vs. Geftinib | EGFR mutation | 5 (12/227) vs.
2 (4/225) |
75 (170/227) vs. 72 (161/225) | (15) | |
| Second-line
and above |
AURA3 (NCT02151981) | III | Osimertinib | EGFR mutation | 1 (4/279) | 71 (198/279) | (16) |
| ARROW (Chinese subgroup) (NCT03037385) | I/II | Pralsetinib (BLU-667) | RET mutation | 3 (1/32) | 56 (18/32) | (17) | |
| LIBRETTO-001 (NCT03157128) | I/II | Selpercatinib | RET mutation | 2 (2/105) | 64 (67/105) | (18) | |
| CodeBreak 100 (NCT03600883) | II | Sotorasib | KRAS G12C mutation NSCLC | 2 (3/124) | 37.1 (46/124) | (19) | |
| NCT02122913 and NAVIGATE (NCT02576431) | I | Larotrectinib | NTRK mutation | 15 (2/13) | 77 (10/13) | (20) | |
| CHRYSALIS (NCT02609776) | I | Amivantamab (JNJ-6372) | EGFR-Exon20ins mutation | 3 (4/81) | 40 (32/81) | (21) | |
| Immunotherapy | |||||||
| First-line | KEYNOTE-024 | III | Pembrolizumab vs. Chemotherapy | PD-L1 + (TPS≥50%) advanced NSCLC | − | 44.8 (69/154) vs.
27.8 (42/151) |
(22) |
| KEYNOTE-024 (5-year follow-up data) | III | Pembrolizumab | Up to 35 cycles/2 years of pembrolizumab | 10 (4/39) | 82 (32/39) | (23) | |
| KEYNOTE-042 (NCT02220894) | III | Pembrolizumab | PD-L1 + (TPS ≥1%) NSCLC | − | 39 (118/299) | (24) | |
| KEYNOTE-799 (NCT03631784) | II | Pembrolizumab + Concurrent chemoradiotherapy | IIIA-C NSCLC | 4 (7/173) | 70 (121/173) | (25) | |
| CheckMate-227
NCT02477826 |
III | Nivolumab
+ Ipilimumab |
PD-L1 + (TPS≥1%) | 5.8 (23/396) | 36 (143/396) | (26) | |
| IMpower130 (NCT02367781) | III | Atezolizumab + Chemotherapy | IV NSCLC | 5 (22/453) | 46 (207/453) | (27) | |
| Impower133 | I/III | Atezolizumab + EP | ES-SCLC | 2.5 (5/201) | 60.2 (121/201) | (28) | |
| Second-line
and above |
KEYNOTE-010 (5-year follow-up data) | II/III | Pembrolizumab | Up to 35 cycles/2 years of pembrolizumab | 15 (12/79) | 94.9 (75/79) | (29) |
| CheckMate-017 (NCT01642004) | III | Nivolumab | Metastatic squamous cell lung cancer | 0.7 (1/135) | 20 (27/135) | (30) | |
| CheckMate-057 (NCT01673867) | III | Nivolumab | Metastatic non-squamous NSCLC | 1.4 (4/292) | 19 (56/292) | (31) | |
| CheckMate-032 (NCT01928394) | I/II | Nivolumab | Recurrent SCLC | 0.9 (1/109) | 12 (13/109) | (32) | |